![]() ![]() Conclusions: We quantified the relative risk of numerous adverse events associated with the use of ACE inhibitors in a variety of demographics. The risk difference was quantified to be 0.037, 0.030, 0.017, and 0.009, respectively. ![]() Results: A total of 378 RCTs fulfilled the eligibility criteria, with 257 RCTs included in the meta-analysis. A random-effects model was used to calculate pooled-effect estimates. The relative risk (RR) and its 95% confidence interval (95% CI) were utilized as a summary effect measure. ![]() Randomized controlled trials (RCTs) comparing an ACE inhibitor to a placebo were retrieved. Methods: Systematic searches were conducted on PubMed, Web of Science, and Cochrane Library databases. This study aimed to systematically determine the adverse effects of ACE inhibitors versus placebo across a wide range of therapeutic settings. Background: Although angiotensin-converting enzyme (ACE) inhibitors are among the most-prescribed medications in the world, the extent to which they increase the risk of adverse effects remains uncertain. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |